Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02968095 · ClinicalTrials.gov registry record · NA

Text Message Support to Prevent Smoking Relapse

A NA study of Tobacco Use Disorder, sponsored by Miami University.

Completed
Registry status
NA
Development phase
58
Enrollment target
1
Study location

NCT02968095: Completed NA study of Tobacco Use Disorder, sponsored by Miami University.

NCT02968095 is a NA study of Tobacco Use Disorder that has completed, run by Miami University. The registered enrollment target is 58 participants, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02968095, a NA study of Tobacco Use Disorder, has completed, sponsored by Miami University.

COMPLETED
Registry status
NA
Development phase
58 participants
Enrollment target
1
Study location

Study Summary

The purpose of this research is to test a text message intervention for people who are beginning an attempt to quit smoking. The intervention seeks to teach people to think about their cravings to smoke in more helpful ways. The investigators expect that participants receiving the text message craving program will be less likely to begin smoking again compared to participants in a control condition.

Primary Outcome

Point prevalence abstinence is defined as the prevalence of not experiencing a full relapse in the period immediately preceding measurement. A full relapse will be defined as 7 continuous days of smoking or smoking ≥ 1 day(s) per week for the two consecutive weeks preceding the time of measurement. Self-reported abstinence will be verified by a Carbon Monoxide assay of breath samples and will override self-report in the direction of smoking.

Conditions Studied

Interventions

  • BEHAVIORAL Text Message Craving Program
  • BEHAVIORAL Self-Help Manual Plus Control Texts

Study Locations (1)

Ohio

  • Miami University - Oxford

Trial Details

FieldValue
Enrollment Target 58 participants
Start Date 2018-08-07
Est. Completion 2019-08-23
Phase NA
Miami University

6 total trials

What the finished NCT02968095 record still lists

NCT02968095 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 58 participants, a relatively small participant target, below the 239-participant average among 70 other Tobacco Use Disorder trials with a reported enrollment target (76% lower).

The record links to 1 condition, with Tobacco Use Disorder appearing as the primary indexed condition, and to 2 interventions - of which Text Message Craving Program is the first listed.

NCT02968095 reports a single indexed study location in Ohio.

Frequently Asked Questions

What is clinical trial NCT02968095 about?

NCT02968095 is a clinical study titled "Text Message Support to Prevent Smoking Relapse". The purpose of this research is to test a text message intervention for people who are beginning an attempt to quit smoking. The intervention seeks to teach people to think about their cravings to smoke in more helpful ways. The investigators expect that participants receiving the text message cravi...

What is the current status of trial NCT02968095?

This trial is currently completed. It is a NA study. The enrollment target is 58 participants. The study started on 2018-08-07. Estimated completion is 2019-08-23.

What conditions does trial NCT02968095 study?

This clinical trial studies the following conditions: Tobacco Use Disorder.

What interventions are being tested in trial NCT02968095?

The interventions under investigation include: Text Message Craving Program (BEHAVIORAL), Self-Help Manual Plus Control Texts (BEHAVIORAL).

Who is sponsoring clinical trial NCT02968095?

This trial is sponsored by Miami University, which has 6 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02968095 being conducted?

This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Tobacco Use Disorder

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02968095's enrollment target sits among peer trials

58 50th of 70 higher than 20 of 70 other Tobacco Use Disorder trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Tobacco Use Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03587844 · 58 participants · Phase 2

    Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients

  • NCT03630991 · 58 participants · Phase 1

    Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy

  • NCT03949855 · 58 participants · Phase 2

    Belimumab With Rituximab for Primary Membranous Nephropathy

  • NCT04069273 · 58 participants · Phase 2

    Novel SEQUEnced Immunotherapy With Anti-angiogenesis and Chemotherapy in Advanced gastroesophageaL Adenocarcinoma

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT02968095, the US trial registry maintained by the National Library of Medicine. NCT02968095 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.